| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 03/06/2002 | EP1183051A2 Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| 03/06/2002 | EP1183049A2 Modification of biological elements |
| 03/06/2002 | EP1183042A2 Methods for treating diabetes |
| 03/06/2002 | EP1183039A1 Pharmaceutical preparations of bioactive substances extracted from natural sources |
| 03/06/2002 | EP1183037A2 Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| 03/06/2002 | EP1183032A1 Method of enhancing insulin action |
| 03/06/2002 | EP1183020A2 Use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia |
| 03/06/2002 | EP1183017A1 Novel formulations comprising lipid-regulating agents |
| 03/06/2002 | EP1183014A1 Controlled release and taste masking oral pharmaceutical compositions |
| 03/06/2002 | EP1183012A1 Novel formulations comprising lipid-regulating agents |
| 03/06/2002 | EP1183011A1 Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto |
| 03/06/2002 | EP0876372B1 Heteroarylcarboxamide derivatives |
| 03/06/2002 | EP0743945B1 Heterocyclic compounds and their preparation and use |
| 03/06/2002 | CN1338946A Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |
| 03/06/2002 | CN1338945A Combination of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications |
| 03/06/2002 | CN1338944A Cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications |
| 03/06/2002 | CN1338937A Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| 03/06/2002 | CN1338936A Drug-combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of P450 |
| 03/06/2002 | CN1338931A Use of anticonvulsant derivatives for treating bulimia nervosa |
| 03/06/2002 | CN1338923A Method for controlling liposome size |
| 03/06/2002 | CN1338275A Chinese-medicinal extract with alpha-glucosidase inhibitor activity, and its preparing process and application |
| 03/06/2002 | CN1338254A Hydroxymethionine salt as trace element additive and its preparing process |
| 03/06/2002 | CN1080295C Antioxidant composition and production thereof |
| 03/06/2002 | CN1080260C Substituted indazole derivatives and their use as phosphodiesterase (PDE) type IV and tumor necrosis factor (TNF) inhibitors |
| 03/06/2002 | CN1080123C Prolonged delivery of peptides |
| 03/05/2002 | US6353128 For treatment of conditions such as septic shock. |
| 03/05/2002 | US6353111 Which increase insulin secretion in the treatment of type ii diabetes; 2,3-di-substituted trans olefinic n-heteroaromatic or urido propionamides: the substitution at the 2-position being a substituted phenyl group and at the 3-position a |
| 03/05/2002 | US6353025 Phenylaminoalkylcarboxylic acid derivatives and pharmaceutical compositions comprising the same |
| 03/05/2002 | US6353023 Aromatic compounds with amide groups |
| 03/05/2002 | US6353018 Compounds, their preparation and use |
| 03/05/2002 | US6353009 Method for the treatment and prevention of hyperuricemia |
| 03/05/2002 | US6353002 Therapeutic agents |
| 03/05/2002 | US6352999 Drugs for nervous system disorders, parkinson's disease and antidepressants |
| 03/05/2002 | US6352990 CRF receptor antagonists and methods relating thereto |
| 03/05/2002 | US6352989 Nitrogenous heterocyclic derivatives and medicine thereof |
| 03/05/2002 | US6352987 Anorectic and antidiabetic agents |
| 03/05/2002 | US6352985 Benzimidazole compounds |
| 03/05/2002 | US6352737 Use of nanoscale sterols and sterol esters |
| 03/05/2002 | US6352692 Lipase inhibiting polymers |
| 03/05/2002 | CA2206122C Arylacrylamide derivatives |
| 03/05/2002 | CA2098735C Novel methylenebisphosphonic acid derivatives |
| 03/05/2002 | CA2098732C Novel methylenebisphosphonic acid derivatives |
| 02/28/2002 | WO2002016632A1 Pharmaceutical compositions comprising a modulator of adamts-1 |
| 02/28/2002 | WO2002016620A2 Modulation of stem cell differentiation |
| 02/28/2002 | WO2002016615A2 Crystal structure of dimethylarginine dimethylaminohydrolase and arginine deiminase |
| 02/28/2002 | WO2002016549A2 METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE |
| 02/28/2002 | WO2002016436A2 ANTIBODIES TO HUMAN IL-1$g(b) |
| 02/28/2002 | WO2002016434A1 T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION |
| 02/28/2002 | WO2002016428A1 Irap-binding protein |
| 02/28/2002 | WO2002016394A1 Thioether-sulphamate steroids as steroid sulphatase inhibitors and anti-cancer compounds |
| 02/28/2002 | WO2002016393A1 17-aryl-linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016392A1 Oestrogen-17-sulphamates as inhibitors of steroid sulphatase |
| 02/28/2002 | WO2002016370A1 1h-imidazopyridine derivatives |
| 02/28/2002 | WO2002016359A1 Fused pyrazole derivatives being protein kinase inhibitors |
| 02/28/2002 | WO2002016352A1 Quinazoline derivatives |
| 02/28/2002 | WO2002016350A1 Amine derivatives |
| 02/28/2002 | WO2002016332A1 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| 02/28/2002 | WO2002016331A1 Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists |
| 02/28/2002 | WO2002016326A1 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases |
| 02/28/2002 | WO2002016319A1 Novel thiourea compounds and the pharmaceutical compositions containing the same |
| 02/28/2002 | WO2002016318A1 Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| 02/28/2002 | WO2002016313A2 Integrin receptor inhibitors |
| 02/28/2002 | WO2002016311A1 Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient |
| 02/28/2002 | WO2002015933A2 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser |
| 02/28/2002 | WO2002015927A1 High mannose proteins and methods of making high mannose proteins |
| 02/28/2002 | WO2002015925A1 Methof of regulating apoptosis and apoptosis-regulatory polypeptide |
| 02/28/2002 | WO2002015920A2 Treatment of hyperproliferative diseases |
| 02/28/2002 | WO2002015917A1 Use of agaricus blazei murill to prevent or treat skin and other disorders |
| 02/28/2002 | WO2002015915A2 Method for inducing an anti-tumor and anti-cachexia immune response in mammals |
| 02/28/2002 | WO2002015909A1 Substituted piperidines as melanocortin receptor agonists |
| 02/28/2002 | WO2002015905A1 The use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity |
| 02/28/2002 | WO2002015892A2 Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors |
| 02/28/2002 | WO2002015879A1 A method of treating a systemic disease |
| 02/28/2002 | WO2002015846A2 Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders |
| 02/28/2002 | WO2002015843A2 Agent for regulating lipidic metabolism and method for producing said agent |
| 02/28/2002 | WO2002009734A8 Sugar absorption inhibitors and process for producing the same |
| 02/28/2002 | WO2001087234A3 Treatment of autoimmune, proliferative and inflammatory diseases with compositions of non-ionic copolymers |
| 02/28/2002 | WO2001085779A3 Protein complexes and assays for screening anti-cancer agents |
| 02/28/2002 | WO2001085762A3 Cancer diagnosis and assays for screening anti-cancer agents |
| 02/28/2002 | WO2001079271A9 Albumin fusion proteins |
| 02/28/2002 | WO2001079258A9 Albumin fusion proteins |
| 02/28/2002 | WO2001073029A3 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof |
| 02/28/2002 | WO2001045714A3 Formulations of adenosine a1 agonists |
| 02/28/2002 | WO2001045661A3 Cosmetic and/or pharmaceutical preparations |
| 02/28/2002 | WO2001042216A3 Caspase inhibitors and uses thereof |
| 02/28/2002 | WO2001031029A3 Human sphingosine kinase gene |
| 02/28/2002 | WO2001027254A3 Gene transfer vectors for treating autoimmune diseases and diseases with immunopathogenesis by therapy |
| 02/28/2002 | WO2001017614A3 Methods and compositions containing succinimide or maleimide derivatives of antineoplastic agents |
| 02/28/2002 | WO2001001970A3 New uses potassium channel openers, such as the treatment of epilepsy |
| 02/28/2002 | WO2000073307A8 Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors |
| 02/28/2002 | WO2000067746A8 Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| 02/28/2002 | WO2000040569A9 2-amino-benzoxazinone derivatives for the treatment of obesity |
| 02/28/2002 | US20020026060 RAR selective retinoid agonists |
| 02/28/2002 | US20020026050 Thrombin receptor antagonists |
| 02/28/2002 | US20020025983 Anticoagulant mixture; cardiovascular disordrs; premenstrual disorders; bone disorders |
| 02/28/2002 | US20020025981 Synergistic mixture of amlodipine and statins |
| 02/28/2002 | US20020025973 Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists |
| 02/28/2002 | US20020025972 Comprehensive pharmacologic therapy for treatment of obesity |
| 02/28/2002 | US20020025966 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments |
| 02/28/2002 | US20020025957 Anticoagulants, cardiovascular disorders |